Form 4: Pfizer Director Echevarria Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Director Joseph Echevarria reports acquisition of phantom stock units representing deferred director's compensation in a recent SEC filing.
Summary
- On September 30, 2024, Joseph Echevarria, a director of Pfizer Inc., acquired 1,598.134 phantom stock units.
- These units represent deferred director's compensation, including dividend equivalents.
- The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
- The price of the underlying common stock was $28.94.
- Following the transaction, Echevarria directly owns 119,944.9 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a standard compensation practice. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
Industry Context
This filing is a routine disclosure of a director's compensation and holdings, which is standard practice for publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it relates to director compensation.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Acquisition of phantom stock units. |
| 10/02/2024 | Date of report: Filing date of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.